IMNN vs. AKTX, ELAB, MIRA, RDHL, PPBT, MNPR, ABVC, KPRX, MBRX, and MTEM
Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Akari Therapeutics (AKTX), Elevai Labs (ELAB), MIRA Pharmaceuticals (MIRA), RedHill Biopharma (RDHL), Purple Biotech (PPBT), Monopar Therapeutics (MNPR), ABVC BioPharma (ABVC), Kiora Pharmaceuticals (KPRX), Moleculin Biotech (MBRX), and Molecular Templates (MTEM). These companies are all part of the "pharmaceutical preparations" industry.
Akari Therapeutics (NASDAQ:AKTX) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 61.8% of Akari Therapeutics shares are held by company insiders. Comparatively, 3.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Akari Therapeutics received 254 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 54.81% of users gave Akari Therapeutics an outperform vote.
In the previous week, Imunon had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Imunon and 1 mentions for Akari Therapeutics. Imunon's average media sentiment score of 0.11 beat Akari Therapeutics' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the media.
Imunon has a consensus price target of $13.00, suggesting a potential upside of 744.16%. Given Akari Therapeutics' higher probable upside, analysts clearly believe Imunon is more favorable than Akari Therapeutics.
Akari Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.
Imunon's return on equity of 0.00% beat Akari Therapeutics' return on equity.
Akari Therapeutics has higher earnings, but lower revenue than Imunon.
Summary
Akari Therapeutics beats Imunon on 7 of the 13 factors compared between the two stocks.
Get Imunon News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
